Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
AssigneeBioxcel Corporation
InventorsKrishnan Nandabalan, Sameer Sharma, Luca Rastelli
Life of this patent
Estimating the term…
Abstract
The invention discloses a method of treating, preventing or ameliorating tumor or symptoms resulting from defective neurofibromatosis type-2 gene in a subject by administering to the subject a therapeutically effective amount of a ubiquitin-proteasome system inhibitor which inhibits or slows the growth of neurofibromatosis type-2-deficient tumor or associated symptoms. The invention also includes methods of diagnosis and screening of patients for neurofibromatosis type-2 and mesothelioma.
Claims25
A method of treating, preventing or ameliorating a tumor or a symptom arising due to a neurofibromatosis type-2 gene mutation in a subject comprising administering to said subject a therapeutically effective amount of bortezomib.
A method of enhancing LATS activity in a tumor having compromised activity of neurofibromatosis type-2/merlin comprising administering bortezomib to a subject having the tumor.
Dependencies are inferred from the claim text.